The international Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR): Relevance to pharmacology today and challenges for the future S. P. Alexander1, A. Christopoulos2, A. P. Davenport3, D. Fabbro4, A. J. Pawson5, J. A. Cidlowski6, K. Kaibuchi7, Y. Kanai8, F. Levi-Schaffer9, E. H. Ohlstein10, J. A. Peters11, A. Phipps12, J. Striessnig13, J. A. Davies5, E. Faccenda5, S. D. Harding5, J. L. Sharman5, C. Southan5, S. J. Enna14, M. Spedding15. 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, United Kingdom, 2Drug Discovery Biology, Monash University, Parkville, Australia, 3Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, United Kingdom, 4PIQUR Therapeutics, PIQUR Therapeutics, Basel, Switzerland, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, United Kingdom, 6Department of Health and Human Services, National Institutes of Health, Research Triangle Park, 7Department of Cell Pharmacology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 8Department of Bio-system Pharmacology, Osaka University, Osaka, Japan, 9Pharmacology and Experimental Therapeutics Unit, The Hebrew University of Jerusalem, Jerusalem, Israel, 10Velicept Therapeutics, Malvern, 11Neuroscience Division, University of Dundee, Dundee, United Kingdom, 12Pharma Research and Early Development (pRED), Roche Innovation Centre Welwyn, Welwyn Garden City, United Kingdom, 13Pharmacology and Toxicology, University of Innsbruck Center for Chemistry and Biomedicine, Innsbruck, Austria, 14Department of Molecular & Integrative Physiology, University of Kansas Medical Center, Kansas City, 15Spedding Research Solutions SARL, Le V‚sinet, France
